title: Network meta-analysis of migraine disorder treatment by NSAIDs and triptans.
abstract: BACKGROUND
  Migraine is a neurological disorder resulting in large socioeconomic burden. This network meta-analysis (NMA) is designed to compare the relative efficacy and tolerability of non-steroidal anti-inflammatory agents (NSAIDs) and triptans.
  
  
  METHODS
  We conducted systematic searches in database PubMed and Embase. Treatment effectiveness was compared by synthesizing direct and indirect evidences using NMA. The surface under curve ranking area (SUCRA) was created to rank those interventions.
  
  
  RESULTS
  Eletriptan and rizatriptan are superior to sumatriptan, zolmitriptan, almotriptan, ibuprofen and aspirin with respect to pain-relief. When analyzing 2 h-nausea-absence, rizatriptan has a better efficacy than sumatriptan, while other treatments indicate no distinctive difference compared with placebo. Furthermore, sumatriptan demonstrates a higher incidence of all-adverse-event compared with diclofenac-potassium, ibuprofen and almotriptan.
  
  
  CONCLUSIONS
  This study suggests that eletriptan may be the most suitable therapy for migraine from a comprehensive point of view. In the meantime ibuprofen may also be a good choice for its excellent tolerability. Multi-component medication also attracts attention and may be a promising avenue for the next generation of migraine treatment.
authors.affiliation: The First hospital of Jilin University, No. 71 Xinmin Street, Changchun, 130021, Jilin, China.
authors.forename: Haiyang
authors.initials: H
authors.lastname: Xu
authors.affiliation: The First hospital of Jilin University, No. 71 Xinmin Street, Changchun, 130021, Jilin, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Han
authors.affiliation: The First hospital of Jilin University, No. 71 Xinmin Street, Changchun, 130021, Jilin, China.
authors.forename: Jinghua
authors.initials: J
authors.lastname: Wang
authors.affiliation: The First hospital of Jilin University, No. 71 Xinmin Street, Changchun, 130021, Jilin, China. limingxian_118@163.com.
authors.forename: Mingxian
authors.initials: M
authors.lastname: Li
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D006801:Humans; D007052:Ibuprofen / Q000627:therapeutic use; D008881:Migraine Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D023303:Oxazolidinones / Q000627:therapeutic use; D011759:Pyrrolidines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D018170:Sumatriptan / Q000627:therapeutic use; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use; D014363:Tryptamines / Q000627:therapeutic use*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D023303:Oxazolidinones; D011759:Pyrrolidines; D014230:Triazoles; D014363:Tryptamines; C409045:almotriptan; C115647:eletriptan; C089750:zolmitriptan; C093622:rizatriptan; D018170:Sumatriptan; D007052:Ibuprofen
keywords: Migraine disorders; Network meta-analysis; Non-steroidal anti-inflammatory agents; Triptans